Skip to main content
BioCentury on BioBusiness
Feature Story

Asthma armament

How Amgen's AMG 282 fits into Genentech's asthma portfolio

By Virginia Li, Staff Writer

Amgen Inc.'s AMG 282 could allow Genentech Inc. to treat an asthma patient population not currently covered by its existing pipeline — or by any other targeted therapies in the clinic. The mAb has a novel mechanism that could serve patients with low levels of Th2 cell cytokine expression.

The deal, which Genentech disclosed on Jan. 28, gives the Roche unit exclusive, worldwide rights to the antibody against IL-1 receptor-like 1 (IL1RL1; ST2). Amgen will receive an undisclosed upfront payment and is eligible for milestones and royalties.

Read Article
  • THE DISTILLERY brings you this week's most essential scientific findings in therapeutics, distilled by Innovations editors from a weekly review of more than 400 papers in 41 of the highest-impact journals in the fields of biotechnology, the life sciences and chemistry. The Distillery goes beyond the abstracts to explain the commercial relevance of featured research, including licensing status and companies working in the field, where applicable.

    This week in therapeutics includes important research findings on targets and compounds, grouped first by disease class and then alphabetically by indication.

    This week in techniques includes findings about research tools, disease models and manufacturing processes that have the potential to enable or improve all stages of drug discovery and development.

Subscribe Now
Free Trial

Management Updates

There were no items published for this section in the most recent issue. Click more >> to read previously published items.

Preclinical Results

There were no items published for this section in the most recent issue. Click more >> to read previously published items.